Inhibition of the Renin Angiotensin System Plus Corticosteroids for the Treatment of Proteinuria in IGA Nephropathy
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00367562 |
Recruitment Status :
Completed
First Posted : August 23, 2006
Last Update Posted : November 1, 2006
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
IGA Nephropathy | Drug: ENALAPRIL VALSARTAN METHYLPREDNISONE | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 20 participants |
Allocation: | Non-Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Phase IV Open Label Uncontrolled Trial of the Dual Blockade of the Renin Angiotensin System With Enalapril Plus Valsartan Combined With Oral Methylprednisolone for the Treatment of Proteinuria in IGA Nephropathy |
Study Start Date : | January 1996 |
Study Completion Date : | December 2005 |

- DAILY PROTEINURIA
- RENAL FUNCTION AS ASSESSED BY SERUM CREATININE

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 21 Years to 70 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- PATIENTES WITH IGA NEPHROPATHY WITH PROTEINURIA OVER 0.5 G/DAY
Exclusion Criteria:
- MALIGNANCY, RENAL FAILURE

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00367562
Argentina | |
Hospital Britanico de Buenos Aires | |
Buenos Aires, Argentina, 1280 |
Principal Investigator: | hernan trimarchi, M.D. | Hospital Britanico |
Publications:
ClinicalTrials.gov Identifier: | NCT00367562 |
Other Study ID Numbers: |
TEREKOWA33 |
First Posted: | August 23, 2006 Key Record Dates |
Last Update Posted: | November 1, 2006 |
Last Verified: | January 1996 |
IGA NEPHROPATHY STEROIDS ENALAPRIL |
VALSARTAN PROTEINURIA IMMUNOGLOBULIN A NEPHROPATHY (IGA NEPHROPATHY) |
Kidney Diseases Proteinuria Glomerulonephritis, IGA Urologic Diseases Urination Disorders Urological Manifestations Glomerulonephritis Nephritis Autoimmune Diseases Immune System Diseases |
Valsartan Enalapril Antihypertensive Agents Angiotensin II Type 1 Receptor Blockers Angiotensin Receptor Antagonists Molecular Mechanisms of Pharmacological Action Angiotensin-Converting Enzyme Inhibitors Protease Inhibitors Enzyme Inhibitors |